V
Vineti
The essential software solution to drive and scale personalized therapies, such as Cell and Gene Therapies or Cancer Vaccines
About Vineti
Vineti is a technology startup that provides a comprehensive platform designed to manage the complex workflows involved in personalized cell and gene therapies. The company serves biopharmaceutical and life science companies, focusing on the development and delivery of personalized medicines for patients with complex diseases. Operating in the personalized medicine market, Vineti's business model revolves around offering a robust, agnostic platform that integrates various aspects of the therapy ecosystem, including manufacturing, supply chain, quality control, IT, commercial, and regulatory teams. The platform ensures full transparency, traceability, and control from specimen collection to the delivery of the final product to the patient. Vineti generates revenue through subscription fees for its software solutions and partnerships with therapy developers. The company aims to optimize resources, speed up deployment, and ensure the highest level of care and transparency in the therapeutic process.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Analytics, Cloud Computing, Data Analytics, Biotechnology, Vaccines, Genetics and genomics, Patient Care, Commerce, Biotech and Pharma, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2020 | $33M | $175M | Threshold Ventures · Canaan · Casdin Capital · McKesson Ventures | — |
| SERIES COther financing | Feb 2020 | $35M | $140M | Canaan · Kite Pharma · Lifeforce Capital · Cardinal Health | ↗ |
Growth signals
Latest recorded traffic for Vineti is 600 monthly website visits, up 71.4% over the last three months. Vineti's team declined 16.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
GE Ventures
Threshold Ventures- LVLifeforce Ventures
Mayo Clinic
Canaan
Section 32
Casdin Capital
Series B and later8 investors entered at this stage
Cardinal Health
Kite Pharma
Lifeforce Capital
Gilead Sciences
Novartis
HIVE Ventures
McKesson Ventures
Marc Benioff
Other known investors2 additional known investors
dRx Capital
Technology Pioneers | World Economic Forum
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vineti on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vineti’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.